secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001213900-24-095423
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M
------------------------------------------------------------------------

- Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
- Cash & investments $249M as of Sep 30; expected to fund operations into Q4 2026.
- Definitive agreement to sell Huntsville PEGylation business to Ampersand for $90M ($70M cash + $20M equity).
- R&D expense rose to $35.0M from $24.1M, driven by rezpegaldesleukin and NKTR-0165 development.
- Topline data for rezpegaldesleukin Phase 2b in atopic dermatitis expected H1 2025; alopecia areata H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/0001213900-24-095423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024095423/ea0220296-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-095423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer